Recombinantly modified plasmin
View Patent ↗Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
1. A polypeptide comprising:
(a) a single N-terminal kringle domain wherein the last four amino acid residues within the single N-terminal kringle domain are identical to residues at positions 91-94 of SEQ ID NO: 2; and
(b) a C-terminal domain activation site and serine protease domain;
wherein the polypeptide binds to immobilized lysine; and
wherein the polypeptide is at least 95% identical to the sequence shown in SEQ ID NO: 2.
2. The polypeptide of claim 1 , wherein the polypeptide is at least 98% identical to the sequence shown in SEQ ID NO: 2.
3. The polypeptide of claim 1 , wherein the polypeptide is the sequence shown in SEQ ID NO: 2.
4. The polypeptide of claim 3 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 15 amino acid substitutions.
5. The polypeptide of claim 3 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 10 amino acid substitutions.
6. The polypeptide of claim 3 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 8 amino acid substitutions.
7. The polypeptide of claim 3 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 5 amino acid substitutions.
8. The polypeptide of claim 3 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 3 amino acid substitutions.
9. The polynucleotide of claim 1 , wherein the polypeptide exhibits a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.
10. The polypeptide of claim 1 , wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.
11. The polypeptide of claim 1 , wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by α2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by α2-antiplasmin.
12. The polypeptide of claim 1 , wherein the rate of inhibition is at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin.
13. The polypeptide of claim 1 , wherein the immobilized lysine is lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-hydrogel, and lysine-cross-linked agarose.
14. The polypeptide of claim 13 , wherein the immobilized lysine is lysine-cross-linked agarose.
15. The polypeptide of claim 1 , wherein the polypeptide has reduced immunogenicity as compared to a reference polypeptide, wherein the reference polypeptide has a primary amino acid sequence identical to the primary amino acid sequence of the polypeptide; with the proviso that the last four amino acid residues of the single N-terminal kringle domain of the reference polypeptide are not identical to residues at positions 91-94 of SEQ ID NO: 2.
16. The polypeptide of claim 1 , wherein the amino acid residues 2-9 of the polypeptide are identical to residues at positions 2-9 of SEQ ID: NO: 2.
17. A pharmaceutical composition comprising:
(a) a single N-terminal kringle domain wherein the last four amino acid residues within the single N-terminal kringle domain are identical to residues at positions 91-94 of SEQ ID NO: 2; and
(b) a C-terminal domain activation site and serine protease domain;
wherein the polypeptide binds to immobilized lysine; and
wherein the polypeptide is at least 95% identical to the sequence shown in SEQ ID NO: 2; and
wherein the polypeptide is a reversibly inactive, acidified polypeptide substantially free of a plasminogen activator.
18. The pharmaceutical composition of claim 17 , wherein the polypeptide is within a concentration range of about 0.1 mg/mL to about 10 mg/mL.
19. The pharmaceutical composition of claim 17 , further comprising a low pH, low buffering capacity agent.
20. The pharmaceutical composition of claim 19 , wherein the composition has a pH between about 2.5 to about 4.0.
21. The pharmaceutical composition of claim 19 , wherein the low pH, low buffering capacity agent is acetic acid, citric acid, hydrochloric acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, aspartic acid, derivatives thereof, or combinations thereof.
22. The pharmaceutical composition of claim 21 , wherein the low pH, low buffering capacity agent is citric acid.
23. The pharmaceutical composition of claim 19 , wherein the low pH, low buffering capacity agent is present at a concentration at which the pH of the composition is raised to a neutral pH by adding no more than about an equal volume of serum to the composition.
24. The pharmaceutical composition of claim 17 , further comprising a stabilizing agent.
25. The pharmaceutical composition of claim 24 , wherein the concentration of the stabilizing agent is in the range of about 0.01 M to about 1.0 M.
26. The pharmaceutical composition of claim 24 , wherein the stabilizing agent is a sugar or sugar alcohol selected from glucose, maltose, mannitol, sorbitol, sucrose, lactose, trehalose, or combinations thereof.
27. The pharmaceutical composition of claim 26 , wherein the stabilizing agent is trehalose.
28. The pharmaceutical composition of claim 17 , wherein the composition is lyophilized.
29. The pharmaceutical composition of claim 17 , wherein the composition is a sterile solution having a pH between about 2.5 and about 4.0 that is suitable for pharmaceutical use directly without neutralization prior to administration, including parenteral administration to humans, that can be raised to physiological pH by adding no more than about 5 volumes of serum to the solution relative to a volume of the solution.
30. The pharmaceutical composition of claim 17 , wherein the polypeptide is at least 98% identical to the sequence shown in SEQ ID NO: 2.
31. The pharmaceutical composition of claim 17 , wherein the polypeptide is the sequence shown in SEQ ID NO: 2.